Revolution Medicines (RVMD) Total Liabilities (2019 - 2026)

Revolution Medicines' Total Liabilities history runs 8 years deep, the most recent figure standing at $753.8 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 162.47% year-over-year to $753.8 million; the TTM figure through Mar 2026 stood at $753.8 million (up 162.47% YoY), while the FY2025 annual figure was $723.2 million, up 146.75% from the prior year.
• Total Liabilities for Q1 2026 stood at $753.8 million, up from $723.2 million in the prior quarter.
• The five-year high for Total Liabilities was $753.8 million in Q1 2026, with the low at $121.0 million in Q1 2023.
• The 5-year median for Total Liabilities is $189.6 million (2024), against an average of $295.8 million.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities decreased 8.16% in 2023, then surged 233.01% in 2025.
• Revolution Medicines' Total Liabilities stood at $126.7 million in 2022, then soared by 85.82% to $235.5 million in 2023, then rose by 24.45% to $293.1 million in 2024, then soared by 146.75% to $723.2 million in 2025, then advanced by 4.23% to $753.8 million in 2026.
• Business Quant data shows RVMD's Total Liabilities at $753.8 million in Q1 2026, $723.2 million in Q4 2025, and $655.0 million in Q3 2025.